Acceleron Named a “Most Honored” Company in Institutional Investor 2020 “All-America Executive Team” Rankings
04 Diciembre 2019 - 3:01PM
Business Wire
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical
company in the discovery and development of TGF-beta superfamily
therapeutics to treat serious and rare diseases, announced today
that it has been included in the recently released Institutional
Investor 2020 “All-America Executive Team” rankings as one of the
country’s “Most Honored” companies.
Institutional Investor is widely considered the leading
publication for institutional investors, including money managers
and pension fund managers. Each year, the publication releases its
All-America Executive Team rankings, which reflect extensive
polling of investment professionals to name the best CEOs, CFOs,
and investor relations (IR) teams. The 2020 rankings are based on
the opinions of nearly 1,700 portfolio managers, buy-side analysts,
and sell-side analysts. This year, nearly 1,500 companies across a
wide range of sectors received votes in the Institutional Investor
polling process, of which only 147 companies were deemed “Most
Honored.”
“We’re pleased to be named a ‘Most Honored’ company in the
latest Institutional Investor rankings, alongside some of this
country’s largest, best-known enterprises,” said Habib Dable,
President and Chief Executive Officer of Acceleron. “This
recognition is a reflection of our concerted effort as a team to
communicate our growth strategy in as transparent, responsive, and
accessible fashion as possible to the investor and analyst
communities.”
Companies earning the “Most Honored” designation had to receive
two or more top-three appearances in the categories of Best CEO,
CFO, IR Professional, and IR Program. Acceleron was also recognized
for its overall IR program as well as for its performance in
metrics of environmental and social responsibility.
About Acceleron
Acceleron is a biopharmaceutical company dedicated to the
discovery, development, and commercialization of therapeutics to
treat serious and rare diseases. The Company's leadership in the
understanding of TGF-beta superfamily biology and protein
engineering generates innovative compounds that engage the body's
ability to regulate cellular growth and repair.
Acceleron focuses its research and development efforts in
hematologic, neuromuscular, and pulmonary diseases. In hematology,
the Company and its global collaboration partner, Bristol-Myers
Squibb, are co-promoting newly approved REBLOZYL®
(luspatercept-aamt), the first and only approved erythroid
maturation agent, in the United States and are developing
luspatercept for the treatment of chronic anemia in myelodysplastic
syndromes and myelofibrosis. Acceleron is also advancing its
neuromuscular program with ACE-083, a locally-acting Myostatin+
agent in Phase 2 development in Charcot-Marie-Tooth disease and is
conducting a Phase 2 pulmonary program with sotatercept in
pulmonary arterial hypertension.
For more information, please visit www.acceleronpharma.com.
Follow Acceleron on Social Media: @AcceleronPharma and
LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191204005857/en/
Acceleron Pharma Inc. Investors: Todd James, IRC, (617) 649-9393
Vice President, Investor Relations and Corporate Communications
Ed Joyce, (617) 649-9242 Director, Investor Relations
Media: Matt Fearer, (617) 301-9557 Director, Corporate
Communications
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024